Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ProMIS Neurosciences Inc PMN

Healthcare Biotechnology
ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.


NDAQ:PMN - Post by User

ProMIS Neurosciences Inc
Bullboard Posts
User Avatar Image
(0)
•••
Post by penguinwinson Nov 01, 2012 8:05am
201 Views
Post# 20548708

Amorfix Antibody Development Program for ALS to be

Amorfix Antibody Development Program for ALS to be

 

Amorfix Antibody Development Program for ALS to be Presented at Leading ALS Conference

TSX: AMF

TORONTO, Nov. 1, 2012 /CNW/ - Amorfix Life Sciences Ltd. announced today that Dr. Neil Cashman, Amorfix Chief Scientific Officer and Company founder, is a lead presenter at today's 8th Annual ALS Therapy Development Institute's Leadership Summit being held in Boston, MA.  He is providing a state-of-the-art overview of Amorfix's therapeutic SOD1 antibody program for the treatment of ALS.

Amorfix is a leader in ALS research and is committed to developing novel diagnostics and therapeutics for ALS.  The Company has identified antibody targets against misfolded SOD1 for the treatment of ALS which have been licensed to Biogen Idec for the development of antibody therapeutics, and to Pan Provincial Vaccine Enterprise (PREVENT) for the development of vaccine applications.  Both of these programs are advancing in preclinical development.  In addition, the Company is developing a blood test to be used as a diagnostic tool for the early detection of ALS, based on the detection and measurement of misfolded SOD1 present in plasma.

 

 

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities